[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-370701-105":59,"doc-detail-370701-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","glp-1-receptor-agonists-and-the-risk-for-cancer-a-meta-analysis-of-randomized-controlled-trials","GLP-1 receptor agonists and the risk for cancer - A meta-analysis of randomized controlled trials","","A meta-analysis evaluates whether GLP-1 receptor agonists differ from comparators in oncogenic risk within randomized controlled trials lasting at least 52 weeks. Fifty trials were included and endpoints covered overall cancers and individual malignancies. Overall cancer risk showed no significant difference, while uterine cancer decreased in obesity-focused studies. Thyroid cancer risk increased, more clearly in longer-term trials, and colorectal cancer showed a short-term increase, with no signal for other cancers.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/glp-1-receptor-agonists-and-the-risk-for-cancer-a-meta-analysis-of-randomized-controlled-trials/370701/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/glp-1-receptor-agonists-and-the-risk-for-cancer-a-meta-analysis-of-randomized-controlled-trials/370701.png","ImageObject",300,407,{"name":92,"@type":93},"Nguyễn Văn Học","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-03","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was the study aim regarding cancer risk?","Question",{"text":112,"@type":113},"To determine whether GLP-1 receptor agonists are associated with a different oncogenic risk compared with comparators in randomized controlled trials.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How many trials were included and what outcomes were analyzed?",{"text":117,"@type":113},"Fifty randomized trials were included, assessing overall cancer incidence and specific malignancies.",{"name":119,"@type":110,"acceptedAnswer":120},"What were the key findings for overall and specific cancers?",{"text":121,"@type":113},"No significant difference was found for overall cancer risk. Uterine cancer was reduced in obesity-related trials, thyroid cancer risk increased, and colorectal cancer showed a significant increase only in shorter-term trials.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},370701,1790539972,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1374402739827,"https://ap-avatar.wpscdn.com/avatar/14000c97e7351f1a627?x-image-process=image/resize,m_fixed,w_180,h_180&k=1787885694763230660","DOI: 10.1111/dom.16489  \nO R IG INA L ARTI CLE  \nGLP-1 receptor agonists and the risk for cancer: A meta-analysis of randomized controlled trials  \nGiovanni Antonio Silverii MD 1  | Christian Marinelli MD 1 | Costanza Bettarini MD 1 | Gloria Giovanna Del Vescovo MD 1 | Matteo Monami PhD 2  | Edoardo Mannucci MD 1   \n1AOU Careggi, Diabetology  \nUnit – Experimental and Clinical Biomedical Sciences “Mario Serio” Department, University of Florence, Florence, Italy  \n2Diabetology Unit, AOU Careggi, Florence, Italy  \nCorrespondence  \nGiovanni Antonio Silverii, Experimental and Clinical Biomedical Sciences “Mario Serio”Department, University of Florence, Largo Brambilla 3, 50134, Florence, Italy.  \nEmail: [giovanniantonio.silverii@unifi.it](giovanniantonio.silverii@unifi.it)  \nAbstract  \nAims: To assess if there is a difference in the oncogenic risk between GLP-1 RA and comparators in randomized controlled trials.  \nMaterials and Methods: A meta-analysis of randomized controlled trials comparing GLP-1RA to any comparators for diabetes and/or obesity, lasting at least 52 weeks. The endpoints included the incidence of overall cancers and single malignancies. Results: Fifty trials were included. GLP-1RA treatment was not associated with a significant difference in risk for overall cancer (MH-OR 1.05, 95% confidence interval [CI][0.98, 1. 13]). Uterine cancer was significantly reduced in the GLP-1RA arm in trials performed in subjects with obesity (MH-OR 0.24, 95% CI [0.06, 0.94]), but not in those aimed at diabetes treatment (MH-OR 0.92, [0.58, 1.47]). We detected an increase in the risk for thyroid cancer (MH-OR 1.55, [1.05, 2.27]), more evident in longer-term trials, and in the risk for colorectal cancer (MH-OR 1.27 [1.03, 1.57]), which, conversely, was significant only in shorter-term trials. No significant difference in the risk was detected for any other cancer. Conclusions: GLP-1 RA do not appear to produce an effect on most malignancies in clinical trials. A reduction of very close obesity-associated cancers seems possible, whereas a risk signal for thyroid cancer was observed, prompting the need for further specific studies. On the other hand, the small increase observed in colorectal cancer in shorter-term trials may be the effect of a disproportionate increase in diagnostic procedures in the GLP-1 RA arm, because of the suspicion raised by common side effects of GLP-1 RA.  \nKEYWOR DS  \ncancer, dulaglutide, exenatide, GLP-1 RA, glucagon-like peptide-1 receptor agonists, liraglutide, meta-analysis, obesity, semaglutide, type 2 diabetes mellitus  \n1 | INTRODUCTION  \nType 2 Diabetes mellitus (T2DM) and obesity have both been associated with an increased incidence of cancer.1–3 The risk is further increased in individuals with both T2DM and obesity4 and in long-term obesity.5 In  \nparticular, 13 malignancies have been identified as obesity-associated cancers, for which the evidence is sufficient to identify obesity as a risk factor6;  \noverall, weight excess may cause up to 20% of total cancer mortality.7  \nThe possible pathogenetic mechanisms implied seem to be different for each neoplasm8: both altered adipocyte function and insulin  \nThis is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.  \n© 2025 The Author(s) . Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd.  \n4454  [wileyonlinelibrary.com/journal/dom](wileyonlinelibrary.com/journal/dom) Diabetes Obes Metab. 2025;27:4454–4468.  \nresistance determine an increase in circulating levels of hormones, such as oestrogens, insulin and insulin-like growth factors, which may in turn enhance tumour proliferation and inhibit apoptosis8; furthermore, adipokines may contribute to oncogenesis by stimulating chronic inflammatory mediators, increasing oxidative stress and impairing immune responses.9 Excess weight is also associa","cbCaiin02cGnBGTn","https://ap.wps.com/l/cbCaiin02cGnBGTn","pdf",3396165,15,"English","# Abstract\n## Aims\n## Materials and Methods\n## Results\n## Conclusions\n# Introduction\n## Diabetes, obesity, and cancer risk\n## Proposed mechanisms","[{\"question\":\"What was the study aim regarding cancer risk?\",\"answer\":\"To determine whether GLP-1 receptor agonists are associated with a different oncogenic risk compared with comparators in randomized controlled trials.\"},{\"question\":\"How many trials were included and what outcomes were analyzed?\",\"answer\":\"Fifty randomized trials were included, assessing overall cancer incidence and specific malignancies.\"},{\"question\":\"What were the key findings for overall and specific cancers?\",\"answer\":\"No significant difference was found for overall cancer risk. Uterine cancer was reduced in obesity-related trials, thyroid cancer risk increased, and colorectal cancer showed a significant increase only in shorter-term trials.\"}]","GLP-1 receptor agonists and the risk for cancer - A meta-analysis of randomized controlled trials | PDF",1790189932,38,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7b8e962656fa2685d8dc9cffe0336dcc.webp",983,1291,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f8f97cd2cadac50f9d833b56257f8563.webp",982,1290,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b191161d2dca1069d6332e496905be58.webp",981,1289,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/58652fe53bafa44ce9a826a42ae9e267.webp",980,1287]